$7495 | Single User
$14990 | Site License
$22485 | Global License

Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 20 Jan 2014 | 93 | In Stock
Related Topics: AstraZeneca , Boehringer Ingelheim , FDA , GlaxoSmithKline , Microbiology , Novartis , Pfizer , Pulmonary , Respiratory

Introduction

Introduction


The prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, its impact on the wider health economy is significant and there remains considerable unmet clinical need. Valued at US billion and with a 5 year CAGR of 7.1% this high growth sector is set for radical change as new products and combinations are introduced changing both the treatment and competitive landscapes.



The cosy carve up of the market between Pfizer’s Spiriva (tiotropium) and GSK’s Advair/Serotide (fluticasone propionate/salmeterol), which currently account for 75% of sales globally, will be challenged by new entrants that provide better patient adherence, improve lung function, tackle inflammation and reduce exacerbations of the disease.



Why is COPD causing such excitement?



There is considerable industry and investor excitement about COPD treatment developments. Which of the new products will find favour with clinicians? What regulatory hurdles must they overcome? Do they offer a real clinical improvement over current therapies? Stripping away the hype and harnessing the real world insights from leading US and European KOL’s, this Therapy Trends analysis critically examines the products and research and exposes the real potential. For example:


  • In September 2013, Novartis’ Ultibro (glycopyrronium/indacaterol) was the first once daily fixed-dose LABA/LAMA to be approved, with promising research results and positive KOL opinion. However, approved dosages of the indacterol element may be lower in the US, which could affect efficacy and take up. Regulatory delay with the FDA is likely to hand the advantage GSK, Boehringer Ingelheim and Almirall/Forest all of whom are likely to bring LABA/LAMA combinations to the US market before Novartis.

  • In May 2013, GlaxoSmithKline’s Breo/Relvar (fluticasone furoate/vilanterol), the first once-daily ICS/LABA was approved, but there are questions over whether it offers clinical value compared with Symbicort and Advair/Serodtide. However, the tide could turn if the product could become the first COPD therapy to gain a mortality claim if the outcome of the SUMMIT trial is positive. In the words of one KOL: “Let's assume that this study is positive. Then the whole field would change dramatically. This would cause an avalanche.”


  • Takeda’s Daxas/Daliresp (roflumilast) was the first, and remains the only, oral PDE-IV inhibitor available but sales are hampered by poor tolerability, unpleasant side effects, variable US formulary coverage and restrictions on use in some EU markets. Chiesi’s CHF 6001 (Phase II) inhaled PDE-IV inhibitor is showing promising and is “extremely well tolerated in extended safety studies.”

  • A Complete Ongoing Analysis of Current Trends, Future Forecasts and Landscape Modifiers



    For instant access to an accurate, unbiased, qualitative review of the latest treatment trends along with a five-year quantitative COPD market forecast look no further than FirstWord’s Therapy Trends: COPD. This comprehensive FirstWord research is available in two comprehensive modules:


  • The KOL Insight: COPD module provides a complete review and is enhanced with exclusive in-depth interviews with leading KOLs from the US and Europe.

  • The Consensus Outlook: COPD data analysis module provides annual historical and forecast product-level sales data from an average of leading equity analysts’ projections. Key findings are provided in report which brings together data in charts and tables.

  • KOL Insight



    KOL Insight Report


  • A qualitative analysis of the current and predicted treatment trends, clinical products and commercial changes in the global COPD market informed by in-depth expert views of leading clinicians

  • Compare the market’s key players, products, late-stage pipeline drugs, product positioning, in the context of COPD market trends.


  • Event Bulletins


  • Benefit from the latest KOL views about significant event driven changes in COPD treatment trends.


  • Consensus Outlook



    Consensus Report


  • An in-depth 5-year Consensus Outlook report of predicted quantitative changes in key COPD market forecast parameters drawn from 13 leading analyst and brokerage companies

  • Chart COPD market size, product sales, market share by company, competitive status and detailed market forecasts


  • Interactive Analytics File


  • Use the interactive Excel market analytics module of detailed market and product sales data from 2007 to 2017 to drill down and assess key company, market and product trends

  • Highlights


    Key Benefits


    Therapy Trends KOL Insight: COPD analyses the current and predicted key issues, current products and late-stage pipeline products. The report gives you qualitative, inside information from exclusive FirstWord interviews with 12 key opinion leaders (KOLs) through the following:


  • KOL Insight Report — an in-depth analytical report on COPD treatment trends

  • Full report updates — issued to you after each and every significant COPD market event

  • Event Bulletins — the latest KOL views in response to each event


  • Key Report Features and Benefits


  • Critical insights on products and market developments from leading US and European clinicians

  • Complete coverage of all therapeutic approaches

  • Assessment of current leading COPD products by sub sector

  • Analysis of late-stage pipeline COPD therapies by sub sector

  • Competitive evaluation of leading players

  • Current thinking and trends in the treatment of COPD and emerging approaches such as Muscarinic antagonist/beta2 agonists

  • Predicted KOL treatment trends and market leaders

  • Ongoing clinical and market updates


  • All current therapeutic approaches covered


  • Long-acting muscarinic antagonists (LAMAs)

  • Long-acting beta2 agonists (LABAs)

  • Phosphodiesterase-IV (PDE-IV) inhibitors

  • Coverage of both their use as monotherapies or in combination


  • Expert Opinion for Real World Insights



    The data and analysis in the report is enriched through the specific insights and opinions of leading clinicians working in COPD in the US and Europe. Their views on specific drugs and treatment pathways provide a unique front line perspective from those working in clinical setting. The results of these detailed and extensive interviews are incorporated though out the text so they can be read in the context of the issue or product being discussed.




    Key Quotes from the Report



    “I think what will be in the best interest of the COPD population is that the LABA/LAMA combination becomes accepted as foundation therapy for anyone with more than mild COPD. Patients who have moderate COPD would benefit most from being on a LABA/LAMA combination.” Professor Christopher Cooper (US)



    “I think we are looking at a major shift. The name of the game here is maximum bronchodilation. We need to provide the maximum bronchodilation as possible. We are working with two different mechanisms of action; so two mechanisms that complement each other so they are not excluding each other, so that they compliment. And that's the market; the way the market is looking and the way the market is shaping up. Everybody is like, 'well, this is probably the way for us to go.” Dr Antonio Anzueto (US)



    “We desperately need new anti-inflammatory agents. That's what will take us to the next level. And this almost lemming rush that pharmaceutical companies have of doing the same thing as somebody else does so you can be the first to the market with it.” Professor Byron Thomashow (US)



    “The problem with Relvar/Breo is when you look at the data when they compared their new drug with their old drug there are no convincing differences. From my point of view it's a once-daily Advair. That's all it is.” Professor Claus Vogelmeier (Europe)


    Consensus Outlook



    Use this detailed report and powerful interactive Excel spread sheet to compare and contrast companies and products now and in the future. Therapy Trends Consensus Outlook: COPD includes the following comprehensive resources:


  • An in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and company performance

  • An interactive forecast data analysis spreadsheet comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017

  • Timely event-driven market forecast report and data analysis updates over 12 months.


  • Report features:


  • Historical COPD sales from 2007–2012

  • Forecast COPD sales from 2013-2017

  • Key competitors and drug developers

  • Current and late-stage pipeline drugs

  • Future event mapping to forecast data points

  • Expected impacting factors on global forecasts




  • Use Consensus Outlook to


  • Chart predicted market growth and product sales

  • Map your own market parameters

  • Tailor your strategic and investment focus

  • Assess your current and future sales resources

  • Set proactive launches and branding strategies


  • Analysts compared


  • Barclays Capital

  • Credit Suisse

  • Deutsche Bank

  • Goldman & Sachs

  • International Strategy & Investment

  • Jefferies

  • JP Morgan

  • Merrill Lynch

  • Morgan & Stanley

  • Societe Generale

  • Stifel Nicolaus

  • UBS

  • Wells Fargo


  • Content Highlights and Products Covered


  • FirstWord Analysis Highlights

  • Research Methodology

  • Chronic Obstructive Pulmonary Disease Marketplace

  • Key Chronic Obstructive Pulmonary Disease Developers

  • Chronic Obstructive Pulmonary Disease Class Dynamics

  • Spiriva (tiotropium; Boehringer Ingelheim/Pfizer) forecast

  • Eklira/Tudorza (aclidinium; Almirall/Forest) forecast

  • Seebri (glycopyrronium; Novartis) forecast

  • Ultibro (glycopyrronium/indacaterol; Novartis) forecast

  • Seretide/Advair (fluticasone propionate/salmeterol; GlaxoSmithKline) forecast

  • Relvar/Breo (fluticasone furoate/vilanterol; GlaxoSmithKline) forecast

  • Symbicort (budesonide/formoterol; AstraZeneca) forecast

  • Arcapta/Onbrez (indacaterol; Novartis) forecast

  • Daliresp/Daxas (roflumilast; Takeda/Forest) forecast

  • Anoro (umeclidinium/vilanterol; GlaxoSmithKline) forecast

  • Aclidinium/formoterol (Almirall/Forest) forecast



  • KOL, Analysts, Products and Companies


    At a glance listings of those who contributed and the rich and varied sources accessed to produce this major analysis of the COPD market and its prospects.



    Key Opinion Leaders


  • Dr Stephen Rennard is Larson Professor in the Department of Internal Medicine and Professor (courtesy) in the Department of Pathology and Microbiology at the University of Nebraska Medical Center

  • Dr Antonio Anzueto is Professor of Medicine, Pulmonary/Critical Care Medicine at University of Texas Health Science Center, San Antonio

  • Dr Donald P. Tashkin is Emeritus Professor of Medicine, Division of Pulmonary and Critical Care Medicine at David Geffen School of Medicine at University of California Los Angeles

  • Dr Edward Eden is Associate Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons

  • Dr Byron Thomashow is a Clinical Professor of Medicine at Columbia University Medical Center and an Attending Physician at the New York-Presbyterian Hospital

  • Professor Christopher Cooper is a Professor of Medicine and Physiology at David Geffen School of Medicine, University of California, Los Angeles

  • Professor Peter Barnes is a Professor of Thoracic Medicine at the National Heart and Lung Institute, Head of Respiratory Medicine at Imperial College and Honorary Consultant Physician at Royal Brompton Hospital, London

  • Dr Marc Miravitlles is Chest Physician & Senior Researcher, Department of Pneumology, Hospital Clinic, Barcelona

  • Dr Rene Aalbers is Consultant Physician, Respiratory Medicine at Martini Hospital, Groningen, The Netherlands

  • Professor Claus Vogelmeier is a Professor of Medicine and Head of Pulmonary Division at Marburg University Hospital, Germany

  • Professor Maurizio Luisetti is a Professor of Respiratory Medicine at the University of Pavia, Italy. Professor Pascal Chanez is a Professor of Medicine, Departement des Maladies Respiratoires, INSERM, Aix Marseille Universite, Marseille, France


  • Analysts


  • Barclays Capital

  • Credit Suisse

  • Deutsche Bank

  • Goldman & Sachs

  • International Strategy & Investment

  • Jefferies

  • JP Morgan

  • Merrill Lynch

  • Morgan & Stanley

  • Societe Generale

  • Stifel Nicolaus

  • UBS

  • Wells Fargo


  • Products & Companies Covered


  • Spiriva (tiotropium; Boehringer Ingelheim/Pfizer)

  • Eklira/Tudorza (aclidinium; Almirall/Forest)

  • Seebri (glycopyrronium; Novartis)

  • Ultibro (glycopyrronium/indacaterol; Novartis)

  • Seretide/Advair (fluticasone propionate/salmeterol; GlaxoSmithKline)

  • Relvar/Breo (fluticasone furoate/vilanterol; GlaxoSmithKline)

  • Symbicort (budesonide/formoterol; AstraZeneca)

  • Arcapta/Onbrez (indacaterol; Novartis)

  • Daliresp/Daxas (roflumilast; Takeda/Forest)

  • Anoro (umeclidinium/vilanterol; GlaxoSmithKline)

  • Aclidinium/formoterol (Almirall/Forest)

  • Ongoing Benefits




    Continually Updated in Response to Market Developments



    The world of pharma is ever changing and executives must always be up- to-date with the latest developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends updated offers real commercial advantage. Consider the benefits:



    Consider the benefits:


  • Content will be fully updated in response to market developments such as new product approvals or pivotal research results for 12 months from the date of purchase

  • Such updates are incorporated throughout the KOL reports ensuring the change is reflected in every aspect of the report

  • There is no limit and all relevant events will result in an update

  • You’ll receive these updates directly, within days of each event’s occurrence

  • All updates are included in the price


  • Whatever happens in the market you’ll always be able to assess the impact with FirstWord Therapy Trends



    Unrivalled Sources Ensure Complete Coverage



    Our unique disease selection matrix pinpoints those disease sectors of the highest commercial potential, and draws information from multiple novel and expert sources, including:


  • Exclusive views from leading global experts

  • Comprehensive consensus research

  • Live dispatches and critical industry data

  • Online opinions from 535,000 vetted physicians

  • Data from over 125 medical conferences each year

  • Over 2,000 peer-reviewed medical journals

  • Over 450 pharmaceutical news sources


  • Table of Contents
    for Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook [Published by FirstWord Pharma]

    • Contents Consensus Outlook

      1.Analysis Highlights

      2.Research Methodology

      3.Chronic Obstructive Pulmonary Disease Marketplace

      4.Key Chronic Obstructive Pulmonary Disease Developers

      5.Chronic Obstructive Pulmonary Disease Class Dynamics

      6.Spiriva (tiotropium; Boehringer Ingelheim/Pfizer) forecast

      7.Eklira/Tudorza (aclidinium; Almirall/Forest) forecast

      8.Seebri (glycopyrronium; Novartis) forecast

      9.Ultibro (glycopyrronium/indacaterol; Novartis) forecast

      10.Seretide/Advair (fluticasone propionate/salmeterol; GlaxoSmithKline) forecast

      11.Relvar/Breo (fluticasone furoate/vilanterol; GlaxoSmithKline) forecast

      12.Symbicort (budesonide/formoterol; AstraZeneca) forecast

      13.Arcapta/Onbrez (indacaterol; Novartis) forecast

      14.Daliresp/Daxas (roflumilast; Takeda/Forest) forecast

      15.Anoro (umeclidinium/vilanterol; GlaxoSmithKline) forecast

      16.Aclidinium/formoterol (Almirall/Forest) forecast

      KOL insight

      1.Executive summary

      2.Introduction

      3.Methodology

      4.Current chronic obstructive pulmonary disease marketplace

      5.Chronic obstructive pulmonary disease overview

      5.1.Epidemiology

      5.2.Aetiology

      5.3.Risk factors

      5.4.Symptoms

      5.5.Diagnosis

      5.6.Chronic obstructive pulmonary disease treatments

      5.6.1.COPD treatment landscape

      5.6.2.COPD market definition

      5.6.3.Current market overview

      5.7.Formulary coverage of chronic obstructive pulmonary disease drugs

      6.Current therapies

      6.1.Key trials with approved therapies

      6.1.2.Spiriva (UPLIFT); FEV1 decline and exacerbations

      6.1.3.Spiriva (POET-COPD): LAMA v LABA, exacerbations

      6.1.4.Advair/Seretide (TORCH): mortality

      6.1.5.Seretide (TRISTAN): lung function and exacerbations

      6.1.6.Spiriva versus Seretide (INSPIRE): exacerbations

      6.1.7.Triple therapy (OPTIMAL): ICS/LABA plus LAMA

      6.2.Long-Acting Muscarinic Antagonists (LAMAs)

      6.2.1.Spiriva (tiotropium; Boehringer Ingelheim/Pfizer)

      6.2.2.Eklira/Tudorza (aclidinium; Almirall/Forest)

      6.2.3.Seebri (glycopyrronium; Novartis)

      6.3.Fixed-dose Long-Acting Muscarinic Antagonist/Long-Acting Beta2 Agonist combinations

      6.3.1.Ultibro (glycopyrronium/indacaterol; Novartis)

      6.3.2.Anoro (umeclidinium/vilanterol; GlaxoSmithKline)

      6.4.Fixed-dose Inhaled Corticosteroid/Long-Acting Beta2 Agonist (ICS/LABA) combinations

      6.4.1.Seretide/Advair (fluticasone propionate/salmeterol; GlaxoSmithKline)

      6.4.2.Relvar/Breo (fluticasone furoate/vilanterol; GlaxoSmithKline)

      6.4.3.Symbicort (budesonide/formoterol; AstraZeneca)

      6.5.Long-Acting Beta2 Agonists (LABAs)

      6.5.1.Arcapta/Onbrez (indacaterol; Novartis)

      6.5.2.Striverdi (olodaterol; Boehringer Ingelheim)

      6.6.Phosphodiesterase-IV (PDE-IV) inhibitors

      6.6.1.Daliresp/Daxas (roflumilast; Takeda/Forest)

      7.Pipeline therapies

      7.1.Fixed-dose Long-Acting Muscarinic Antagonist/Long-Acting Beta2 Agonist (LAMA/LABA) 7.2.combinations

      7.2.1.Tiotropium/olodaterol (Boehringer Ingelheim)

      7.2.2.Aclidinium/formoterol (Almirall/Forest)

      7.2.3.Glycopyrronium/formoterol (AstraZeneca/Pearl Therapeutics)

      7.3.Fixed-dose triple ICS/LAMA/LABA combinations

      7.3.1.Chiesi’s triple fixed-dose combination

      7.3.2.GlaxoSmithKline’s Ellipta device: a platform for triple therapies

      7.4.Muscarinic antagonists/beta2 agonists (MABAs)

      7.5.Novel anti-inflammatories and anti-oxidants

      8.Treatment focus

      8.1.Unmet needs in chronic obstructive pulmonary disease

      8.1.1.Unmet need 1: Novel agents that modify disease progression and/or reduce exacerbations

      8.1.2.Unmet need 2: Early detection of COPD

      8.1.3.Unmet need 3: Improving patient drug adherence

      8.1.4.Unmet need 4: Confirming COPD diagnosis

      8.1.5.Unmet need 5: Understanding the mechanism of action of COPD drugs

      8.2.Current chronic obstructive pulmonary disease treatment algorithm

      8.2.1.GOLD guidelines

      8.2.2.NICE guidelines (England and Wales)

      8.3.Device is not a deciding factor in selecting treatments

      8.4.Current chronic obstructive pulmonary disease treatment practice

      8.4.1.Treatment practice: US

      8.4.2.Treatment practice: England

      8.4.3.Treatment practice: Spain, France, Italy

      8.4.4.Prescribing point 1: ICS are widely used to treat COPD

      8.4.5.Prescribing point 2: Free-dose ICS are not approved for COPD in the US or EU

      8.4.6.Prescribing point 3: FDA’s heightened risk attitude towards LABAs

      8.4.7.Prescribing point 4: EMA and FDA have approved different doses

      9.1.Future chronic obstructive pulmonary disease treatment algorithm

      9.2.LAMA/LABAs provide maximum bronchodilation

      9.3.LAMA/LABAs introduce a drug sequencing issue

      9.4.ICS withdrawal is a key resistor to LAMA/LABA uptake

      9.5.Commercial success of Combivent supports LAMA/LABA US uptake

      9.6.Comparative data with ICS/LABAs could accelerate clinical adoption of LAMA/LABAs

      10.Future treatment landscape

      10.1.Smoking cessation vaccines

      10.2.Novel vaccines and anti-virals to reduce exacerbations

      10.3.Novel endpoints

      10.4.Generic drugs

      11.Appendix

      11.1indication specific sales

      11.2.KOL biographies

      11.3.KOLs from US

      11.4.KOLs from Europe

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    93 |

    Number of Pages

    158

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Global Acute and Chronic Myelogenous Leukemia Partnering 2010 to 2016
    The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
    01 Oct 2016 by Current Partnering USD $1,495 More Info
    Global Chronic Kidney Disease Partnering 2010 to 2016
    The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
    01 Oct 2016 by Current Partnering USD $1,495 More Info
    The Outlook for Wearable Health Tech in Managing Chronic Disease
    IntroductionWearable tech – the new golden ticket for patient adherence?Wearable technology is being...
    01 May 2016 by FirstWord Pharma USD $695 More Info
    Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin [Feb 2016]
    IntroductionThis edition presents key opinion leader (KOL) views on recent developments in the chron...
    01 Feb 2016 by FirstWord Pharma USD $995 More Info
    Chronic Lymphocytic Leukaemia: Update Bulletin [Feb 2016]
    IntroductionGain new KOL insights on the latest events with the potential to shape the targeted trea...
    01 Feb 2016 by FirstWord Pharma USD $995 More Info
    Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2015
    Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2015SummaryGlobalD...
    30 Oct 2015 by Global Data USD $2,500 More Info
    Chronic Lymphocytic Leukaemia: KOL Insight
    IntroductionIn the last few years the emergence of new targeted therapies such as AbbVie’s/Janssen’s...
    01 Sep 2015 by FirstWord Pharma USD $7,900 More Info
    Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
    IntroductionCombination therapy is set to take centre stage in the treatment of COPD as leading comp...
    20 Apr 2015 by FirstWord Pharma USD $7,900 More Info
    Chronic Lymphocytic Leukaemia: KOL Insight
    IntroductionChronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until rece...
    27 May 2014 by FirstWord Pharma USD $7,900 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...